Senate Ups Funding for Alzheimer’s Research by $350 million for 2020
Bringing the total NIH funding for Alzheimer’s research up to $2.8 billion, the Senate continued its steady upward climb in spending for the disease.
ALL NEWS
6556 RESULTS
Sort By:
- Most Recent
- Most Commented
Going Indirect: Can Therapies Halt Alzheimer’s from Outside the Brain?
Apabetalone, an epigenetic drug that tamps down vascular inflammation, slowed cognitive decline in people with MCI. A new statistical analysis of results from AMBAR claimed the plasma-exchange therapy might boost cognition by removing pathogenic proteins from blood.
Picking Through the Rubble, Field Tries to Salvage BACE Inhibitors
At CTAD, researchers discussed possible paths forward. One option: exploring whether low doses prevent plaque accumulation while avoiding the cognitive side effects.
Amyloid Clearance: Check. Cognitive Benefit: Um … Maybe.
Plaque-busting antibodies reset the time course of amyloid accumulation, but so far provide only hints of a clinical benefit in mild AD. Good news: once gone, plaque stays gone for a while.
Blood Tests of Phospho-Tau, Aβ42, Track With Brain Amyloid
Using mass spectrometry to detect teensy amounts of phospho-tau species in plasma, researchers reported that p-tau-217 and p-tau-181 picked out people with Aβ pathology. Differences between groups appear to be huge. An MS-based test for plasma Aβ42 corresponded to brain amyloid, and is going in for regulatory approval.
Fluid AD Biomarkers Link P-Tau to Synapses, Inflammation
An expanded set of CSF biomarkers exposed tight connections between p-tau, synaptic dysfunction, and neuroinflammation in people with brain amyloid.
Exposure, Exposure, Exposure? At CTAD, Aducanumab Scientists Make a Case
Biogen researchers claim the antibody worked in people who got enough of it. To other researchers, the signal validates the amyloid hypothesis and injects fresh energy into the field. But is this interrupted dataset enough to approve?
To Monitor Neurons, Microglia Talk With the Boss, aka the Soma
Prior research has focused on microglia interacting with synapses. New data show they also deal directly with the neuronal cell body. Like little conference rooms, specialized junctions host this communication.
Gosuranemab, Biogen’s Anti-Tau Immunotherapy, Does Not Fly for PSP
In PASSPORT study, the antibody failed to slow progressive supranuclear palsy. Alzheimer’s trial to continue.
Clinical Trials on Alzheimer's Disease 2019
Exposure, Exposure, Exposure? At CTAD, Aducanumab Scientists Make a Case Fluid AD Biomarkers Link P-Tau to Synapses, Inflammation Blood Tests of Phospho-Tau, Aβ42, Track With Brain Amyloid Amyloid Clearance: Check. Cognitive Benefit: Um … Maybe. Picking T
Does a Breached Blood-Brain Barrier Cause Seizures in AD?
Researchers link age-related weakening of the barrier to TGFβ signaling, hyperexcitation, and cognitive problems. In rodents, TGFβ antagonists attenuate these effects, reducing seizures.
Lysosomal Diseases: Stepping Stones to Gene Therapy for Alzheimer’s?
While gene-based therapy for late-onset AD may seem distant, rare neurological disorders could point the way.
Society for Neuroscience Annual Meeting 2019
Not Just Blood Pressure—Dietary Salt Linked to Tau Phosphorylation Time to Try Again: Gene-Based Therapy for Neurodegeneration Gene Therapies Enter Trials for Many Brain Pathologies—What about AD? Organized around 10 major themes, this year’s annual meeti
Gene Therapies Enter Trials for Many Brain Pathologies—What about AD?
As gene therapy is making a comeback, scientists are exploring if it might prevent or reverse Alzheimer’s. Some of those treatments are permanent, heightening safety concerns.
Time to Try Again: Gene-Based Therapy for Neurodegeneration
Encouraged by success in treating infant spinomuscular atrophy, researchers are redoubling their efforts to target genetic causes of age-related neurodegeneration.
Current Filters
No filters selected